PharmaLifeSciences 2024: Advancements in Cell and Gene Therapy

The rapid advancements in cell and gene therapies have transformed the treatment landscape for various conditions, including cancer, genetic disorders, and autoimmune diseases. However, the reimbursement environment for these groundbreaking therapies presents unique challenges and opportunities. In this session, Monet Stanford, PharmD, Director of Access & Reimbursement Policy at the Alliance for Regenerative Medicine, will explore the current realities of the payer environment, focusing on Medicare and Medicaid and the emerging models of value-based pricing and outcomes-based agreements.